COVER STORY • 封面專題 2024 UMAGAZINE 30 • 澳大新語 9 also dedicated to developing products that meet international standards and possess branding potential. In October 2020, the Macao SAR Government approved the establishment of MCR&DCM, bringing together resources to drive product development and commercialisation. The centre collaborates with universities in mainland China, leading companies specialising in Chinese medicine, and institutions in Beijing, Hong Kong, and Macao. Prof Li Peng, deputy director of ICMS and director of MCR&DCM, explains that SKL-QRCM has established joint laboratories with leading universities and companies from mainland China, leading to more than 20 collaborative projects that cover innovative drug research, the development of classical prescriptions, the enhancement of premier ingredients, and the development of health and wellness products. ‘By partnering with enterprises in mainland China, we have advanced several classical Chinese medicine prescriptions into pilot production and initiated the registration process here in Macao,’ says Prof Li. In addition, SKL-QRCM researchers have secured numerous patents in Chinese medicine, and incubated many Chinese medicine technology enterprises. Supporting Pharmaceutical Testing and Regulation MCTCM was officially inaugurated in November 2024. The centre is positioned as an authority on Chinese medicine quality control. Distinguished Professor Li Shaoping, deputy director of SKL-QRCM and director of MCTCM, explains, ‘MCTCM offers comprehensive testing services—from registration and production to logistics and export. We also take on government-assigned tasks such as registration, supervision, arbitration, and emergency testing, and we provide technical support for businesses.’ Strengthening regulatory sciences in key areas of Chinese medicine can enhance the innovative development of the regulatory concepts, systems, and mechanisms in Chinese medicine. It will also facilitate the commercialisation of research findings and accelerate the development and market entry of new products. To strengthen regulatory capabilities for healthcare products in Macao and across the Guangdong-Hong Kong-Macao Greater Bay Area, and promote cross-sectoral, cross-regional, and international collaboration, UM established CPRS in 2023. The centre’s key functions include assisting the Pharmaceutical Supervision and Administration Bureau of Macao with technical evaluations of proprietary Chinese medicines and medical devices; conducting research on regulatory science, policy, and legal frameworks; developing new regulatory tools, standards, and methods for drug evaluation and regulatory decision-making. Promoting Academic Collaboration In addition to its research efforts, SKL-QRCM actively collaborates with universities worldwide. In October 2023, the laboratory launched the Traditional Medicine Innovation Alliance with leading universities from Singapore, Hong Kong, Malaysia, 2024年8月，為落實「澳大與深圳市藥品檢驗研究院戰略合作框架協議」，深圳市藥品檢驗研究院向澳大中藥檢測中心捐贈100份中藥標本。 To implement the strategic cooperation framework agreement signed with UM, the Shenzhen Institute for Drug Control donated 100 Chinese medicine specimens to the Macao Centre for Testing of Chinese Medicine in August 2024.
RkJQdWJsaXNoZXIy NzM0NzM2